Anesthesia and analgesia
-
Anesthesia and analgesia · Jul 2010
Editorial CommentManaging neuromuscular block: where are the guidelines?
-
Anesthesia and analgesia · Jul 2010
Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Cannabinoid receptor 2 (CB2) agonists have recently gained attention as potential therapeutic targets in the management of neuropathic pain. In this study, we characterized the pharmacological profile of the novel compound N'-[(3Z)-1-(1-hexyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide (MDA19), a CB2 agonist. ⋯ We found that MDA19 exhibited a distinctive in vitro functional profile at rat CB2 receptors and behaved as a CB1/CB2 agonist in vivo, characteristics of a protean agonist. MDA19 has potential for alleviating neuropathic pain without producing adverse effects in the central nervous system.